Search Results for "ATTRv"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Effect of RNAi Therapeutics Patisiran and Vutrisiran on Orthostatic Hypotension Due to Dysautonomia in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial

NfL Levels Significantly Decrease in Response to Treatment with Patisiran or Vutrisiran in hATTR Amyloidosis with Polyneuropathy

Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study

Effectiveness of Patisiran Following Switch From Tafamidis for the Treatment of Hereditary Transthyretin Mediated (hATTR) Amyloidosis with Polyneuropathy

Impact of Baseline Polyneuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study

Neurofilament Light Chain as a Biomarker in Hereditary Transthyretin-Mediated Amyloidosis: 36-Month Data from the Patisiran Global Open-Label Extension

Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis

Impact of Vutrisiran on Activities of Daily Living and Functional Status in Patients with hATTR Amyloidosis

ATTRv-PN Expert Opinion Slide Deck

Recommendations from a panel of experts for the diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.